ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, ...

Seth Wander, MD, PhD, discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative ...

TNBC, aggressive and lacking key receptors, complicates treatment, impacting prognosis and requiring specialized approaches.

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast ...

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...

With the average age for women to be diagnosed with breast cancer is late forties, one woman revealed she was diagnosed with ...

“I was crying all the time and he did not like that. He was very concerned about me. He really turned into my healing buddy. He was a greater purpose for me.” Last spring, with Mochi by her side, ...

Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer.

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.